Enterome
Privately owned personalized medicine company
会社概要
Enterome is a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health. Enterome’s success is based on its unique ability to identify small proteins and peptides (“effectors”) from gut bacteria that can deliver a therapeutic benefit in humans. Enterome is leveraging this unique ability to develop two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer, inflammatory and metabolic diseases: - OncoMimics: highly effective, off-the-shelf immunotherapies against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463, is about to enter clinical development for indolent non-Hodgkin B-cell lymphomas. - EndoMimics: a new generation of biologics targeting inflammatory diseases (EM101) and metabolic diseases such as Type 2 diabetes. These pipelines have been created using Enterome’s highly efficient proprietary drug discovery platform that uses machine learning and lab assays to interrogate and decode the world’s largest database of gut bacterial proteins, a unique source of novel precision drugs. In addition, Enterome’s clinical candidate Sibofimloc (also referred to as TAK-018) is advancing through Phase 2 clinical trials in Crohn’s disease. Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US. Enterome is headquartered in Paris (France) and is backed by leading venture capital investors.
日付 | 投資家 | 数量 |
---|
投資家 | 数量 |
---|
最近のニュース
SINEORA(シンノラ)と共に、フランスのVIVATECHに日本からライブで参加!
国内にいながらViva Technology(パリ開催)参加の効果を得られる、Viva Technology主催者公認サイドイベントを札幌で開催!
SINEORA Online Seminar #3: 5G opportunity in Japan and France
SINEORA supports The Futures Project for the UN’s 75th anniversary
SINEORA has launched its new monthly Online seminar series !
このスタートアップと会う